197 related articles for article (PubMed ID: 30077642)
1. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
[TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Arch Toxicol; 2018 Sep; 92(9):2845-2857. PubMed ID: 29992508
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
4. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Bukum N; Novotna E; Morell A; Hofman J; Wsol V
Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
[TBL] [Abstract][Full Text] [Related]
5. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment.
He S; Chu X; Wu Y; Jiang J; Fang P; Chen Y; Liu Y; Qiu Z; Xiao Y; Li Z; Pan D; Zhang Q; Xie H; Xing S; Feng F; Liu W; Guo Q; Zhao L; Yang P; Sun H
J Med Chem; 2023 Jul; 66(14):9537-9560. PubMed ID: 37409679
[TBL] [Abstract][Full Text] [Related]
6. Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Matsunaga T; Okumura N; Saito H; Morikawa Y; Suenami K; Hisamatsu A; Endo S; Ikari A
Chem Biol Interact; 2020 Dec; 332():109295. PubMed ID: 33096057
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.
Morell A; Novotná E; Milan J; Danielisová P; Büküm N; Wsól V
Arch Toxicol; 2021 Jan; 95(1):67-78. PubMed ID: 33025066
[TBL] [Abstract][Full Text] [Related]
8. Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
Morsy A; Trippier PC
ACS Chem Biol; 2020 Mar; 15(3):646-650. PubMed ID: 32125151
[TBL] [Abstract][Full Text] [Related]
9. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
10. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
11. Instability of C154Y variant of aldo-keto reductase 1C3.
Endo S; Takada S; Honda RP; Müller K; Weishaupt JH; Andersen PM; Ludolph AC; Kamatari YO; Matsunaga T; Kuwata K; El-Kabbani O; Ikari A
Chem Biol Interact; 2017 Oct; 276():194-202. PubMed ID: 28025170
[TBL] [Abstract][Full Text] [Related]
12. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
13. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review.
Karunasinghe N; Masters J; Flanagan JU; Ferguson LR
Curr Cancer Drug Targets; 2017; 17(7):603-616. PubMed ID: 28359237
[TBL] [Abstract][Full Text] [Related]
14. Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Verma K; Zang T; Penning TM; Trippier PC
J Med Chem; 2019 Apr; 62(7):3590-3616. PubMed ID: 30836001
[TBL] [Abstract][Full Text] [Related]
15. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
[TBL] [Abstract][Full Text] [Related]
16. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells.
Matsunaga T; Kawabata S; Yanagihara Y; Kezuka C; Kato M; Morikawa Y; Endo S; Chen H; Iguchi K; Ikari A
Chem Biol Interact; 2019 Dec; 314():108839. PubMed ID: 31563593
[TBL] [Abstract][Full Text] [Related]
19. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
20. Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells.
Yamashita N; Kanno Y; Saito N; Terai K; Sanada N; Kizu R; Hiruta N; Park Y; Bujo H; Nemoto K
Biochem Biophys Res Commun; 2019 Aug; 516(3):693-698. PubMed ID: 31253396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
